
1. j neurovirol. 2011 jun;17(3):288-90. doi: 10.1007/s13365-011-0027-4. epub 2011
apr 13.

natalizumab hsv meningitis.

shenoy es(1), mylonakis e, hurtado rm, venna n.

author information: 
(1)division infectious diseases, massachusetts general hospital, gray-jackson 
504, 55 fruit street, boston, 02114, usa. eseiguershenoy@partners.org

natalizumab (tysabri, biogen idec elan pharmaceuticals) monoclonal
antibody approved use patients relapsing multiple sclerosis (ms) as
well moderate severe crohn's disease. report first case patient
with history ms, monthly natalizumab, developed hsv-2 meningitis. 
discuss mechanism action natalizumab review known the
reactivation herpes infection association medication. the
question herpes simplex virus (hsv) varicella zoster virus (vzv)
prophylaxis patients raised.

doi: 10.1007/s13365-011-0027-4 
pmcid: pmc3105891
pmid: 21487835  [indexed medline]

